Last updated: February 16, 2026
What is the current market status for NDCL 52536-0170?
The drug with National Drug Code (NDC) 52536-0170 is marketed as Selumetinib (Koselugo), developed by AstraZeneca. It received FDA approval in April 2020 for treating pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. The drug was granted orphan drug designation and has shown promise in targeted therapy for rare genetic tumor conditions.
How is the market for Selumetinib structured?
Selumetinib's market comprises:
- Orphan drug segment targeting NF1-associated plexiform neurofibromas.
- Pediatric oncology market focusing on rare tumor treatments.
- Off-label uses potentially expanding into other genetic or tumor types based on ongoing clinical trials.
Key elements impacting patent protections and exclusivity:
- Patents granted in the U.S. extend to approximately 2035, with data exclusivity lasting until 2025.
- Fast track, orphan drug, and rare pediatric disease designations accelerate market entry but don't extend exclusivity.
Who are the main market drivers?
Market drivers include:
- Increasing diagnosis rates of NF1, estimated at 1 in 3,000 births globally (NIH).
- Lack of approved treatments before Selumetinib's approval.
- Clinical trial data demonstrating significant tumor shrinkage, leading to positive prescribing trends.
- Incentives linked to orphan drug status.
What is the current price point for NDc 52536-0170?
Initial pricing set by AstraZeneca in the U.S.:
| Timeframe |
Price per Capsule for 25 mg |
Annual Cost Estimate for Full Dose (at typical dosing) |
| Post-approval (2020) |
~$9,000 |
~$120,000 per year |
Pricing varies based on dosage, regimen, and payer negotiations.
- No significant discounts or biosimilar entries have emerged due to patent and exclusivity protections.
- The European market has similar pricing, adjusted for currency and healthcare system differences, approximately €7,500 per 25 mg capsule.
What are the price projections over the next five years?
| Year |
Estimated Price per Capsule |
Key Factors |
Estimated Annual Revenue Impact |
| 2023 |
$9,000 |
Patent protection intact, steady demand |
Approximately $240 million in U.S. sales (assuming consistent prescribing patterns) |
| 2024 |
$8,500 - $9,000 |
Potential negotiation for discounts, patent expiry risk |
Slight decrease expected due to discounting pressure |
| 2025 |
$8,000 - $8,500 |
Data exclusivity expiring in 2025, many payers negotiating rebates |
Revenue decline expected without new indications or formulations |
| 2026-2027 |
$7,500 - $8,000 |
Entry of potential biosimilars or generics after patent expiry |
Market erosion possible, contingent on regulatory and patent decisions |
What are the key risks and opportunities impacting price?
Risks:
- Patent cliff post-2025 data exclusivity expiration.
- Entry of biosimilars or generics could reduce prices.
- Price negotiations and reimbursement policies tightening.
Opportunities:
- Expansion into adult populations or additional tumor types.
- New formulations or combination therapies could sustain premium pricing.
- Expanded clinical data validating long-term efficacy could justify price maintenance.
Which factors could influence the future of NDc 52536-0170?
- Regulatory decisions relating to exclusivity and patent challenges.
- Clinical trial outcomes that could lead to expanded indications.
- Healthcare policy changes affecting orphan drug reimbursement.
- Competitive developments from potential pipeline drugs or biosimilars.
Summary of competitive landscape
| Company |
Product/Development Focus |
Patent Status |
Market Share (est.) |
| AstraZeneca |
Selumetinib |
Patents till ~2035 |
Dominant early player |
| Future entrants |
Biosimilars, generic MEK inhibitors |
Likely post-2025 |
Potentially increasing |
Conclusion
The pricing outlook for NDc 52536-0170 (Selumetinib) remains relatively stable until patent exclusivity ends around 2025. Current pricing of approximately $9,000 per capsule sustains a high-margin orphan drug profile, though the market may face downward pressure afterward. Investment and R&D decisions should factor in patent expiry risks, potential pipeline developments, and regulatory dynamics.
Key Takeaways
- Selumetinib's high price is supported by orphan drug status, limited competition, and proven efficacy.
- Market revenues are expected to plateau or decline post-2025 due to patent expiry.
- There is potential for expanded indications that could prolong exclusivity and stabilize pricing.
- Biosignals exiting the market after patent expiry could prompt generic competition.
- Reimbursement and negotiation trends could influence future prices downward.
FAQs
1. Will the price of NDc 52536-0170 decrease after patent expiration?
Yes. Biosimilars or generics could enter the market once patent protections end, leading to price reductions.
2. Are there approved biosimilars for Selumetinib?
No, currently no biosimilars are approved. Patent expiry is expected around 2035, providing a window for competitors.
3. Can the drug's dosing or formulation impact future pricing?
Yes. New formulations or combination therapies may maintain or increase pricing despite patent expirations.
4. How does clinical trial data influence the price?
Robust data demonstrating long-term efficacy and safety can justify premium pricing, impacting reimbursement negotiations.
5. What is the potential for global market expansion?
European and other international markets are adopting Selumetinib with pricing similar to U.S. levels, but reimbursement strategies vary.
Sources
- FDA. (2020). Koselugo (Selumetinib) Approval Letter.
- NIH. (2022). Neurofibromatosis Type 1 (NF1).
- AstraZeneca. (2022). Selumetinib (Koselugo) Patents and Orphan Status.
- Industry estimates. (2023). Orphan drug pricing and market projections.
